Company intelligence / Profile preview

Revotek

Chengdu, Sichuan, Chinarevotek.com ↗

Ownership: Private
Employees: ~30
Development stage: Preclinical

Overview

Received clearance from the National Health Commission of China to begin a clinical study for REVOVAS, their first stem cell 3D bioprinting product for patients with Peripheral Artery Diseases (PADs). The clinical trial was anticipated to start in Q2 2022[5].

Therapeutic areas: Cardiovascular
Modalities: Stem cell technologies3D bioprinting
Industry: Implantable Medical Devices

Drug pipeline

1 asset

3D bioprinted blood vessels

Pre-clinical

Indications: Vascular disease

Partnerships

West China Hospital of Sichuan University

Beyond the preview

Go deeper on Revotek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revotek.

Explore the full profile